Evidence map›Paper›PMID 33920896›Full record

ArticleJournal of personalized medicine2021

Compound Haplotype Variants in

Agnieszka Furmańczyk-Zawiska, Anna Kubiak-Dydo, Ewelina Użarowska-Gąska, Marta Kotlarek-Łysakowska, Katarzyna Salata, Monika Kolanowska, Michał Świerniak, Paweł Gaj, Beata Leszczyńska, Maria Daniel and 3 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Agnieszka Furmańczyk-ZawiskaDepartment of Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, Poland.
Anna Kubiak-DydoWarsaw Genomics INC, 01-682 Warsaw, Poland.
Ewelina Użarowska-GąskaWarsaw Genomics INC, 01-682 Warsaw, Poland.ORCID 0000-0002-0443-4733
Marta Kotlarek-ŁysakowskaWarsaw Genomics INC, 01-682 Warsaw, Poland.ORCID 0000-0002-6703-1253
Katarzyna SalataWarsaw Genomics INC, 01-682 Warsaw, Poland.
Monika KolanowskaWarsaw Genomics INC, 01-682 Warsaw, Poland.
Michał ŚwierniakWarsaw Genomics INC, 01-682 Warsaw, Poland.
Paweł GajWarsaw Genomics INC, 01-682 Warsaw, Poland.
Beata LeszczyńskaDepartment of Pediatrics Nephrology, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0001-6811-4934
Maria DanielDepartment of Pediatrics Nephrology, Medical University of Warsaw, 02-091 Warsaw, Poland.ORCID 0000-0002-6525-0882
Krystian JażdżewskiWarsaw Genomics INC, 01-682 Warsaw, Poland.
Magdalena DurlikDepartment of Transplantation Medicine, Nephrology and Internal Diseases, Medical University of Warsaw, 02-006 Warsaw, Poland.ORCID 0000-0002-4798-1497
Anna WójcickaWarsaw Genomics INC, 01-682 Warsaw, Poland.
Medical University of Warsaw · PLUniversity of Warsaw · PL

Funding

Program of the Ministry of Science and Higher Education Implementation Doctorate 50//DW/2017/01/1Warsaw Genomics, the Foundation for Polish Science Team-Tech Program POIR.04.04.00-00-41DB/17
6 · The paper itself

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare disease triggered by dysregulation of the alternative complement pathway, consisting of a characteristic triad of nonimmune hemolytic anemia, thrombocytopenia, and renal failure. The risk of aHUS onset, recurrence, and allograft loss depends on the genetic background of a patient. We show a series of cases from a single family whose five members were affected by aHUS and presented distinct clinical outcomes. Next-generation sequencing revealed combined mutations in both complement factor H and membrane cofactor protein CD46. Out of eight siblings, aHUS affected three adult brothers, and, subsequently, affected two children of an unaffected sister. The first patient died due to aHUS, and two other brothers underwent successful kidney transplantation with no aHUS recurrence. The younger, 10-month-old child presented with a severe course of the disease with cardiac involvement and persistent hemolytic anemia limited by eculizumab, while the 2-year-old recovered completely on eculizumab. The study shows a highly variable disease penetrance.

Indexed as

aHUSCD46CFHhemolytic-uremic syndromekidney transplantation

Identifiers

PMID33920896
PMCPMC8071215
OpenAlexW3156868964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.